SymbolZBIO
NameZENAS BIOPHARMA, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1000 WINTER ST,SUITE 1200, WALTHAM, Massachusetts, 02451, United States
Telephone857-271-2954
Fax
Email
Websitehttps://www.zenasbio.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001953926
Description

Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases.

Additional info from NASDAQ:
Zenas BioPharma is a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. We leverage our experienced executive management team and our established networks throughout the biopharmaceutical industry to identify, acquire and develop product candidates that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Our lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We are developing obexelimab for patients in several autoimmune diseases.

2026-08-19 20:15

📋 Zebra Aggregator, LP (Affiliate) plans to sell 1.0M shares of ZENAS BIOPHARMA INC (at $31.91 each, total $31.9M) Filed: Aug 19, 2026 | ID: 000858

Read more
2026-08-19 19:50

New Form SCHEDULE 13D/A - Zenas BioPharma, Inc. <b>Filed:</b> 2026-08-19 <b>AccNo:</b> 0001953107-26-000015 <b>Size:</b> 9 KB

Read more
2026-08-18 20:15

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-08-17 20:00

New Form SCHEDULE 13D/A - Zenas BioPharma, Inc. <b>Filed:</b> 2026-08-17 <b>AccNo:</b> 0001072613-26-000694 <b>Size:</b> 153 KB

Read more
2026-07-17 20:15

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more
2026-06-17 22:09

Nunn Jason Raleigh 🟢 acquired 18.5K shares (1 derivative) of Zenas BioPharma, Inc. (ZBIO) at $18.71 Transaction Date: Jun 15, 2026 | Filing ID: 274473

Read more
2026-06-17 22:03

Director Lu Hongbo 🟢 acquired 18.5K shares (1 derivative) of Zenas BioPharma, Inc. (ZBIO) at $18.71 Transaction Date: Jun 15, 2026 | Filing ID: 075257

Read more
2026-06-17 22:02

Director MOULDER LEON O JR 🟢 acquired 500.0K shares (1 derivative) of Zenas BioPharma, Inc. (ZBIO) at $18.71 ($9.4M) Transaction Date: Jun 15, 2026 | Filing ID: 075256

Read more
2026-06-17 22:02

Director ORLOFF JOHN J 🟢 acquired 18.5K shares (1 derivative) of Zenas BioPharma, Inc. (ZBIO) at $18.71 Transaction Date: Jun 15, 2026 | Filing ID: 075255

Read more
2026-06-17 22:02

von Moltke Lisa 🟢 acquired 150.0K shares (1 derivative) of Zenas BioPharma, Inc. (ZBIO) at $18.71 ($2.8M) Transaction Date: Jun 15, 2026 | Filing ID: 075254

Read more